Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$109.46 USD

109.46
480,575

+2.03 (1.89%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $109.54 +0.08 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for JAZZ

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Jazz Pharmaceuticals PLC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,626 881 591 2,133 1,077
Receivables 706 651 563 396 356
Notes Receivable 0 0 0 0 0
Inventories 597 714 1,073 95 79
Other Current Assets 506 359 384 215 118
Total Current Assets 3,435 2,606 2,611 2,840 1,630
Net Property & Equipment 170 228 257 128 132
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 484 386 323 260 229
Intangibles 7,171 7,487 8,980 3,153 3,361
Deposits & Other Assets 67 55 41 26 48
Total Assets 11,393 10,835 12,299 6,536 5,539
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 103 91 100 27 48
Current Portion Long-Term Debt 605 31 31 246 33
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 794 803 666 353 268
Income Taxes Payable 35 8 10 25 11
Other Current Liabilities 0 0 2 3 5
Total Current Liabilities 1,537 933 809 654 364
Mortgages 0 0 0 0 0
Deferred Taxes/Income 848 944 1,301 133 229
Convertible Debt 0 0 0 0 0
Long-Term Debt 5,108 5,693 6,019 1,849 1,574
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 105 107 117 101 109
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 7,656 7,750 8,333 2,876 2,428
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 3,700 3,477 3,535 2,634 2,266
Retained Earnings 879 734 831 1,160 1,068
Other Equity -842 -1,126 -400 -134 -223
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 3,737 3,086 3,965 3,660 3,111
Total Liabilities & Shareholder's Equity 11,393 10,835 12,299 6,536 5,539
Total Common Equity 3,737 3,086 3,965 3,660 3,111
Shares Outstanding 62.90 62.90 61.40 55.70 56.50
Book Value Per Share 59.41 49.06 64.58 65.70 55.06

Fiscal Year End for Jazz Pharmaceuticals PLC falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,626 1,586 1,362 1,168
Receivables NA 706 628 610 624
Notes Receivable NA 0 0 0 0
Inventories NA 597 612 657 675
Other Current Assets NA 506 420 380 318
Total Current Assets NA 3,435 3,246 3,010 2,785
Net Property & Equipment NA 170 222 229 228
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 484 472 438 408
Intangibles NA 7,171 7,123 7,448 7,488
Deposits & Other Assets NA 67 76 66 64
Total Assets NA 11,393 11,204 11,261 11,047
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 103 110 98 125
Current Portion Long-Term Debt NA 605 605 31 31
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 794 770 748 712
Income Taxes Payable NA 35 89 68 40
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 1,537 1,573 945 909
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 848 841 911 932
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 5,108 5,111 5,687 5,690
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 127 127 109
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 7,656 7,715 7,735 7,712
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 3,700 3,640 3,580 3,512
Retained Earnings NA 879 885 812 803
Other Equity NA -842 -1,035 -867 -980
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 3,737 3,489 3,526 3,335
Total Liabilities & Shareholder's Equity NA 11,393 11,204 11,261 11,047
Total Common Equity 0 3,737 3,489 3,526 3,335
Shares Outstanding 63.00 62.90 63.10 64.10 64.00
Book Value Per Share 0.00 59.41 55.30 55.00 52.11